 DEVON, Pa., May 27, 2021 GLOBE NEWSWIRE -- Zynerba Pharmaceuticals, Inc. Nasdaq: ZYNE, the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at the 2021 American Society of Clinical Psychopharmacology ASCP Annual Meeting. The ASCP annual meeting is being held virtually June 1-4, 2021. A copy of the poster will be made available on the Zynerba corporate website at the time of presentation at 